JP2021501202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501202A5 JP2021501202A5 JP2020543258A JP2020543258A JP2021501202A5 JP 2021501202 A5 JP2021501202 A5 JP 2021501202A5 JP 2020543258 A JP2020543258 A JP 2020543258A JP 2020543258 A JP2020543258 A JP 2020543258A JP 2021501202 A5 JP2021501202 A5 JP 2021501202A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 69
- 150000003839 salts Chemical class 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- -1 4-methyl-piperazine-1-yl Chemical group 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000002757 morpholinyl group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 230000009529 traumatic brain injury Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims description 4
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 238000010922 spray-dried dispersion Methods 0.000 claims description 4
- 230000002123 temporal effect Effects 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 102000016252 Huntingtin Human genes 0.000 claims description 2
- 108050004784 Huntingtin Proteins 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 102000013498 tau Proteins Human genes 0.000 claims description 2
- 108010026424 tau Proteins Proteins 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 6
- 0 *c(cc1)c(*)cc1S(c(cc1)cc(*)c1N(C=NN1)C1=S)(=O)=O Chemical compound *c(cc1)c(*)cc1S(c(cc1)cc(*)c1N(C=NN1)C1=S)(=O)=O 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 5
- 230000003959 neuroinflammation Effects 0.000 description 5
- BJWHWZOMLHXKPF-UHFFFAOYSA-N O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)cc(C(F)(F)F)c1Cl)=O Chemical compound O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)cc(C(F)(F)F)c1Cl)=O BJWHWZOMLHXKPF-UHFFFAOYSA-N 0.000 description 4
- LVSRXKVDSYTMNS-UHFFFAOYSA-N O=S(c(cc1C(F)(F)F)ccc1Cl)(c(cc1N2CCOCC2)ccc1N(C=NN1)C1=S)=O Chemical compound O=S(c(cc1C(F)(F)F)ccc1Cl)(c(cc1N2CCOCC2)ccc1N(C=NN1)C1=S)=O LVSRXKVDSYTMNS-UHFFFAOYSA-N 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- MLJOILDVPRGUBB-UHFFFAOYSA-N CC(C=CC(C1)S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)=C1C(F)(F)F Chemical compound CC(C=CC(C1)S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)=C1C(F)(F)F MLJOILDVPRGUBB-UHFFFAOYSA-N 0.000 description 2
- JGYMLRFLRKQKFK-UHFFFAOYSA-N CCOCCCOc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S Chemical compound CCOCCCOc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S JGYMLRFLRKQKFK-UHFFFAOYSA-N 0.000 description 2
- PFGRCDCBWOEEFM-UHFFFAOYSA-N CCOCCOC(C1)=CC=CC1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O Chemical compound CCOCCOC(C1)=CC=CC1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O PFGRCDCBWOEEFM-UHFFFAOYSA-N 0.000 description 2
- DDASGMSESIJHPI-UHFFFAOYSA-N CN(CC1)CCN1c1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S Chemical compound CN(CC1)CCN1c1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S DDASGMSESIJHPI-UHFFFAOYSA-N 0.000 description 2
- XGXYECKJJHUMNY-UHFFFAOYSA-N COCCOc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 Chemical compound COCCOc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 XGXYECKJJHUMNY-UHFFFAOYSA-N 0.000 description 2
- PWHDKJDNBVLTPG-UHFFFAOYSA-N COc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O Chemical compound COc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O PWHDKJDNBVLTPG-UHFFFAOYSA-N 0.000 description 2
- XDKARSCTAIMMMH-UHFFFAOYSA-N Cc(cc(cc1)S(Cc(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1Cl Chemical compound Cc(cc(cc1)S(Cc(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1Cl XDKARSCTAIMMMH-UHFFFAOYSA-N 0.000 description 2
- ZYYUGYKDUZBBPG-UHFFFAOYSA-N Cc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O Chemical compound Cc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O ZYYUGYKDUZBBPG-UHFFFAOYSA-N 0.000 description 2
- VVZLDBPRESTKMI-UHFFFAOYSA-N Cc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 Chemical compound Cc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 VVZLDBPRESTKMI-UHFFFAOYSA-N 0.000 description 2
- DYPHXJSMKFKFEV-UHFFFAOYSA-N N#Cc1cc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)ccc1 Chemical compound N#Cc1cc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)ccc1 DYPHXJSMKFKFEV-UHFFFAOYSA-N 0.000 description 2
- NVUMIZYTPVJJFQ-UHFFFAOYSA-N O=S(c(cc1)cc(C(F)(F)F)c1Cl)(c(cc1N2CCCC2)ccc1N(C=NN1)C1=S)=O Chemical compound O=S(c(cc1)cc(C(F)(F)F)c1Cl)(c(cc1N2CCCC2)ccc1N(C=NN1)C1=S)=O NVUMIZYTPVJJFQ-UHFFFAOYSA-N 0.000 description 2
- NBAWEYFXKDHXDB-UHFFFAOYSA-N O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)ccc1N1CCOCC1)=O Chemical compound O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)ccc1N1CCOCC1)=O NBAWEYFXKDHXDB-UHFFFAOYSA-N 0.000 description 2
- BKXODGURHNZWOJ-UHFFFAOYSA-N O=S(c1ccccc1)(c(cc1)ccc1N(C=NN1)C1=S)=O Chemical compound O=S(c1ccccc1)(c(cc1)ccc1N(C=NN1)C1=S)=O BKXODGURHNZWOJ-UHFFFAOYSA-N 0.000 description 2
- WQWQZKLHSMNXSN-UHFFFAOYSA-N OCCNc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S Chemical compound OCCNc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S WQWQZKLHSMNXSN-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076473A JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579070P | 2017-10-30 | 2017-10-30 | |
| US62/579,070 | 2017-10-30 | ||
| US201762584630P | 2017-11-10 | 2017-11-10 | |
| US62/584,630 | 2017-11-10 | ||
| PCT/US2018/058050 WO2019089478A1 (en) | 2017-10-30 | 2018-10-29 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076473A Division JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501202A JP2021501202A (ja) | 2021-01-14 |
| JP2021501202A5 true JP2021501202A5 (enExample) | 2021-11-18 |
| JP7277473B2 JP7277473B2 (ja) | 2023-05-19 |
Family
ID=66333645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543258A Active JP7277473B2 (ja) | 2017-10-30 | 2018-10-29 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
| JP2023076473A Pending JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076473A Pending JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10501423B2 (enExample) |
| EP (1) | EP3703675A4 (enExample) |
| JP (2) | JP7277473B2 (enExample) |
| KR (1) | KR102639231B1 (enExample) |
| CN (1) | CN111372579B (enExample) |
| AU (1) | AU2018359224B2 (enExample) |
| BR (1) | BR112020008727A2 (enExample) |
| CA (1) | CA3080578A1 (enExample) |
| IL (1) | IL274010B2 (enExample) |
| MX (1) | MX2020004202A (enExample) |
| SG (1) | SG11202003879RA (enExample) |
| WO (1) | WO2019089478A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020008727A2 (pt) | 2017-10-30 | 2020-10-20 | Neuropore Therapies, Inc. | fenil sulfonil fenil triazol tionas substituídas e usos destas |
| US20210290597A1 (en) * | 2018-06-20 | 2021-09-23 | Neuropore Therapies, Inc. | Method of treating a condition associated with neurodegeneration using inhibitors of oat3 |
| CN117384029B (zh) * | 2023-12-12 | 2024-02-20 | 山东国邦药业有限公司 | 一种2,4,5-三氟苯乙酸的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1476503A (en) | 1973-06-21 | 1977-06-16 | Sterling Drug Inc | 1-arylamino-and 1-arylimino-pyrroles and preparation thereof |
| US4279637A (en) | 1979-06-02 | 1981-07-21 | Velsicol Chemical Corporation | Herbicidal N-substituted 4-imidazolin-2-ones |
| DE3307506A1 (de) | 1983-03-03 | 1984-09-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Fotografisches aufzeichnungsmaterial mit inhibitorvorlaeuferverbindungen |
| US5108486A (en) * | 1990-02-09 | 1992-04-28 | Kanagawa Chemical Laboratory, Ltd. | Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones |
| WO2003024441A1 (en) | 2001-09-14 | 2003-03-27 | Shionogi & Co., Ltd. | Novel use of tricyclic compound |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| DE10123586A1 (de) | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| US20020183306A1 (en) | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| RU2223952C2 (ru) | 2001-06-04 | 2004-02-20 | Институт физиологически активных веществ РАН | Производные n,s-замещенных n'-1-[(гетеро)арил]-n'-[(гетеро)арил]метилизотиомочевин или их солей с фармакологически приемлемыми кислотами нх, способы получения их солей и оснований, фармацевтическая композиция, способ лечения и способ изучения глутаматэргической системы |
| SE0301232D0 (sv) * | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| BRPI0411867A (pt) | 2003-07-09 | 2006-08-08 | Hoffmann La Roche | tiofenilaminoimidazolinas |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| US20050228031A1 (en) | 2004-04-13 | 2005-10-13 | Bilodeau Mark T | Tyrosine kinase inhibitors |
| US7008748B1 (en) * | 2004-09-07 | 2006-03-07 | Eastman Kodak Company | Silver salt-toner co-precipitates and imaging materials |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US20060217390A1 (en) | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| KR20080019213A (ko) | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| US20060276464A1 (en) | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| WO2007005785A1 (en) | 2005-07-04 | 2007-01-11 | Dr. Reddy's Laboratories Ltd. | Thiazoles derivatives as ampk activator |
| PL2013204T3 (pl) | 2006-03-24 | 2015-09-30 | Array Biopharma Inc | Analogi 2-aminopirydyny jako aktywatory glukokinazy |
| MX2009004947A (es) * | 2006-11-09 | 2009-05-19 | Hoffmann La Roche | Arilsulfonil-pirrolidinas como inhibidores 5-hidroxitriptaminas6 (5-ht6). |
| HRP20151398T1 (hr) | 2006-12-22 | 2016-02-12 | Astex Therapeutics Limited | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze |
| WO2008118718A2 (en) | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| BRPI0816881A2 (pt) | 2007-09-21 | 2015-03-17 | Array Biopharma Inc | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. |
| PE20091315A1 (es) | 2008-01-09 | 2009-09-21 | Array Biopharma Inc | Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt |
| US9271962B2 (en) | 2008-03-17 | 2016-03-01 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| KR102142753B1 (ko) | 2009-03-27 | 2020-09-14 | 히타치가세이가부시끼가이샤 | 열경화성 수지 조성물, 및 이를 이용한 프리프레그, 지지체 부착 절연 필름, 적층판 및 인쇄 배선판 |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| RU2016116533A (ru) * | 2010-09-03 | 2018-11-30 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| CA2881472A1 (en) | 2012-08-09 | 2014-02-13 | Neuropore Therapies, Inc. | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways |
| US20140044813A1 (en) * | 2012-08-09 | 2014-02-13 | Kemin Industries, Inc. | Plant Extracts for Improving Cognitive Health and Function |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| BR112020008727A2 (pt) | 2017-10-30 | 2020-10-20 | Neuropore Therapies, Inc. | fenil sulfonil fenil triazol tionas substituídas e usos destas |
-
2018
- 2018-10-29 BR BR112020008727-0A patent/BR112020008727A2/pt unknown
- 2018-10-29 EP EP18873686.2A patent/EP3703675A4/en not_active Withdrawn
- 2018-10-29 WO PCT/US2018/058050 patent/WO2019089478A1/en not_active Ceased
- 2018-10-29 CN CN201880071304.3A patent/CN111372579B/zh not_active Expired - Fee Related
- 2018-10-29 MX MX2020004202A patent/MX2020004202A/es unknown
- 2018-10-29 JP JP2020543258A patent/JP7277473B2/ja active Active
- 2018-10-29 AU AU2018359224A patent/AU2018359224B2/en not_active Ceased
- 2018-10-29 SG SG11202003879RA patent/SG11202003879RA/en unknown
- 2018-10-29 KR KR1020207015547A patent/KR102639231B1/ko active Active
- 2018-10-29 CA CA3080578A patent/CA3080578A1/en active Pending
-
2019
- 2019-03-27 US US16/366,793 patent/US10501423B2/en active Active
- 2019-10-24 US US16/663,054 patent/US11008294B2/en not_active Expired - Fee Related
-
2020
- 2020-04-16 IL IL274010A patent/IL274010B2/en unknown
-
2021
- 2021-04-06 US US17/223,989 patent/US11708338B2/en active Active
-
2023
- 2023-05-08 JP JP2023076473A patent/JP2023100842A/ja active Pending
- 2023-06-05 US US18/206,005 patent/US20230391734A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7719769B2 (ja) | 抗ウイルスプロドラッグ及びその医薬組成物 | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| CN107530348B (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| KR102216381B1 (ko) | 에다라본 및 (+)-2-보르네올의 설하 약학 조성물 | |
| JP2021501202A5 (enExample) | ||
| AU2017326791A1 (en) | Medicinal composition | |
| JP2022123032A (ja) | エダラボン医薬組成物 | |
| JP2016525102A5 (enExample) | ||
| TWI884912B (zh) | 喹啉酮類似物及其鹽、組合物及其使用方法 | |
| KR20170081228A (ko) | 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법 | |
| JP2019501879A5 (enExample) | ||
| US20150064252A1 (en) | Solid dispersion formulation of an antiviral compound | |
| TW201501730A (zh) | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 | |
| US20220339141A1 (en) | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein | |
| JP7617898B2 (ja) | Ｅｙｐ００１を使用した改善された処置 | |
| KR20250005363A (ko) | 인간 병원체 감염의 예방 및/또는 치료에서 hpk1 억제제의 용도 | |
| WO2012087257A2 (en) | Oral dosage form comprising imatinib and production of said oral dosage form | |
| AU2016331073A1 (en) | Combination therapy regimen for treatment of HCV | |
| KR101282847B1 (ko) | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 | |
| JP2017505313A5 (enExample) | ||
| JP5932829B2 (ja) | 経口活性ヌクレオチドアナログ又は経口活性ヌクレオチドアナログプロドラッグの高度に安定な組成物 | |
| KR20170118700A (ko) | (1e,4e)-2-아미노-n,n-디프로필-8-(4-(피롤리딘-1-카보닐)페닐)-3h-벤조[b]아제핀-4-카복사미드를 포함하는 고체형, 이의 조성물, 및 이의 용도 | |
| JP2019516765A5 (enExample) | ||
| RU2018142381A (ru) | Фармацевтический препарат | |
| JPH025735B2 (enExample) |